A consensus statement on the use of biosimilar medicines in hematology in Australia-Reference-Cited by-同舟云学术

A consensus statement on the use of biosimilar medicines in hematology in Australia

Published:2020-04-14 Issue:4 Volume:16 Page:211-221
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Gregory Gareth P.¹²^ORCID,Carrington Christine³⁴^ORCID,Cheah Chan Y.⁵⁶,Hawkes Eliza A.⁷⁸,Irving Ian M.⁹¹⁰,Siderov Jim¹¹,Opat Stephen¹²¹²

Affiliation:

1. Monash HaematologyMonash Health Clayton Victoria Australia

2. School of Clinical Sciences at Monash HealthMonash University Clayton Victoria Australia

3. Department of PharmacyPrincess Alexandra Hospital Brisbane Queensland Australia

4. School of PharmacyUniversity of Queensland Brisbane Queensland Australia

5. Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA Nedlands Western Australia Australia

6. Medical School of Pathology and Laboratory MedicineUniversity of Western Australia Crawley Western Australia Australia

7. Olivia Newton‐John Cancer Research & Wellness CentreAustin Health Melbourne Victoria Australia

8. Eastern Health Melbourne Victoria Australia

9. The Wesley Hospital Auchenflower Queensland Australia

10. Icon Group Brisbane Queensland Australia

11. Department of PharmacyAustin Health Melbourne Victoria Australia

12. Clinical HaematologyAlfred Health Melbourne Victoria Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13337

Reference48 articles.

1. Australian Government—Department of Health.Biosimilars awareness initiative. How have biosimilar medicines been used around the world?http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-how-have-biosimilar-medicines-been-used-around-the-world. Accessed August 2019.

2. Australian Government—Department of Health.Market research for the pharmaceutical benefits schedule (PBS) and biosimilar medicines.https://www1.health.gov.au/internet/main/publishing.nsf/Content/BA5ACD557142FED5CA25808A00809863/$File/market-research-report-09-2016.pdf. Accessed August 2019.

3. A survey of Australian prescribers’ views on the naming and substitution of biologicals

4. Australian Government—Department of Health.TGA. Prescription medicines: registration of new generic medicines and biosimilar medicines 2017.https://www.tga.gov.au/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017. Accessed August 2019.

5. Australian Government—Department of Health.TGA. Australian public assessment report for Rituximab. Available from:https://www.tga.gov.au/sites/default/files/auspar-rituximab-180823.pdf. Accessed August 2019.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey;Frontiers in Pharmacology;2022-06-02

2. Substitution and interchangeability: time for a conversation?;GABI J;2022

3. A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma;Leukemia & Lymphoma;2021-07-29

4. A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma;2021-03-26

5. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar);Internal and Emergency Medicine;2020-06-10